Spiros is a biopharmaceutical business expert and deal-maker with over 20 years experience in the biotech industry. He has extensive understanding of both scientific principles with business strategy and has a track record in commercialising biopharmaceuticals that include gene therapy, vaccines and RNA therapeutics assets. Spiros has helped secure over $110M in upfront payments through 30+ partnerships, totaling over $7B in value. Through combining scientific expertise with business acumen, he is able to consistently deliver exceptional results. Spiros has held key positions at Oxford Gene Technology, Emergent BioSolutions & Oxford BioMedica. He holds a PhD in molecular biology and a MBA from Imperial College, London.
Experience includes:
- Partnering
- Disposition of Assets
- Due Diligence
- Scouting for New Technologies
- Alliance Management
- Business Intelligence
- Valuations (Risk adjusted NPVs)
- Commercialisation Evaluation
